A003120 Share Price Performance
Recent A003120 News & Updates
No updates
Ilsung Is Co., Ltd. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 2.20k
- Gross Margin
- 40.34%
- Net Profit Margin
- 21.97%
- Debt/Equity Ratio
- 0%
Ilsung Is Co., Ltd. Competitors
About A003120
- Founded
- 1954
- Employees
- n/a
- CEO
- WebsiteView website
Ilsung Is Co., Ltd. operates as a pharmaceutical company in South Korea. Its products include antibiotics, analgesics, muscle relaxants, antipyretic-analgesics, antihistamine, neuropsychiatric, neuromuscular blocker/ central muscle relaxants, anti-coagulants, probiotics, vaccine, medical equipment, circulatory system drugs, contrast agents, muscle relaxants, diabetes treatments, osteopathic, digestive system medicines, anti-virals, anti-emetics, respiratory treatments, adrenal cortical steroids, anesthetics, antipyretics, and cardiovascular system products. The company was formerly known as Ilsung Pharmaceuticals Co., Ltd. and changed its name to Ilsung Is Co., Ltd. in April 2024. Ilsung Is Co., Ltd. was founded in 1954 and is headquartered in Seoul, South Korea.
South Korean Market Performance
- 7 Days: 1.5%
- 3 Months: 24.6%
- 1 Year: 13.5%
- Year to Date: 32.5%
The market is up 1.5% over the last week, with the Information Technology sector leading the way, up 5.3%. In the last year, the market has climbed 14%. Earnings are forecast to grow by 21% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading